107 results
F-1
EX-10.11
IMCR
Immunocore Holdings plc
15 Jan 21
Registration statement (foreign)
4:57pm
AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
Amended & Restated Global Access Commitments Agreement
This Amended … & Restated Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”), is entered into as of 2 March
DRS/A
EX-10.10
IMCR
Immunocore Holdings plc
22 Dec 20
Draft registration statement (amended)
12:00am
AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
Amended & Restated Global Access Commitments Agreement
This Amended … & Restated Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”), is entered into as of 2 March
F-1/A
EX-10.12
IMCR
Immunocore Holdings plc
1 Feb 21
Registration statement (foreign) (amended)
6:21am
AND (II) IS THE TYPE THAT THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
FIRST AMENDMENT
TO
AMENDED AND RESTATED GLOBAL ACCESS COMMITMENTS … AGREEMENT
This FIRST AMENDMENT TO AMENDED AND RESTATED GLOBAL ACCESS COMMITMENTS AGREEMENT (“Agreement”) is dated as of the day of February, 2021
F-1/A
EX-10.12
IMCR
Immunocore Holdings plc
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
AND (II) IS THE TYPE THAT THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
FIRST AMENDMENT
TO
AMENDED AND RESTATED GLOBAL ACCESS COMMITMENTS … AGREEMENT
This FIRST AMENDMENT TO AMENDED AND RESTATED GLOBAL ACCESS COMMITMENTS AGREEMENT (“Agreement”) is dated as of the 3rd day of February, 2021
6-K
EX-99.1
IMCR
Immunocore Holdings plc
26 Jan 22
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
4:29pm
Application. Additionally, Immunocore launched a global early access program to make KIMMTRAK readily available to mUM patients. There are currently … over 200 patients in 13 countries in the early access program.
Immunocore is committed to helping patients who need KIMMTRAK obtain access via its
6-K
EX-99.3
5jjst0n4hw2 wl1argii
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
F-1/A
EX-4.3
s2pyw7cnrnox5agu
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
EX-10.19
m5632usbg
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
EX-10.19
yevdeh7yhdt3c6k ga
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
6-K
EX-99.2
cakti zzde
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
nf1dy6xm xxynvqhzl
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
F-1/A
EX-4.3
39pi2wnelwpqg3y446
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-1
EX-10.15
72jm1
15 Jan 21
Registration statement (foreign)
4:57pm
6-K
EX-99.1
nnv5v6v96
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.1
87fic6do99
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
shqnc0
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
aq2co
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
frbsnh44drdj2qg
18 Apr 23
Current report (foreign)
4:13pm
DRS/A
EX-10.14
19hoqud2u2
22 Dec 20
Draft registration statement (amended)
12:00am
6-K
EX-99.2
28nelkz89ndcehb55m1l
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am